바이옴엑스(PHGE)는 NYSE MKT에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.68 (-5.42%), 시가총액 $0.01B, 52주 최저~최고 $0.26 ~ $7.50.
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company's phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from which single optimal phages are personally matched to treat specific patients. It develops BX011, a fixed multi-phage cocktail, which is in Phase 2a trial for the treatment of diabetic foot infection
바이옴엑스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
바이옴엑스의 현재 주가는 $0.68 (-5.42%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
바이옴엑스의 시가총액은 약 $0.01B입니다.
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated